Stockscreener 앱 받기
7.54
2.58%
-0.20
시간 외 거래:
7.48
-0.06
-0.80%
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Growth in Short Interest - MarketBeat
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet - Yahoo Finance
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference - GlobeNewswire
Monte Rosa Therapeutics to Present at Jefferies Healthcare Conference: MGD Innovation Spotlight | GLUE Stock News - StockTitan
FMR LLC Increases Stake in Monte Rosa Therapeutics Inc - GuruFocus.com
News Flash: Analysts Just Made A Sizeable Upgrade To Their Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Forecasts - Simply Wall St
Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), - Yahoo Finance
Wedbush Equities Analysts Raise Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns “Outperform” Rating from Wedbush - Defense World
Monte Rosa Therapeutics Expands Pipeline with Novartis Deal - TipRanks
Monte Rosa Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada
Monte Rosa Therapeutics: Q3 Earnings Snapshot - Barchart
Monte Rosa Therapeutics Inc (GLUE) Quarterly 10-Q Report - Quartzy
Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN
Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice - MSN
Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Monte Rosa Secures $2.1B Novartis Deal, Extends Cash Runway to 2028 in Major Pipeline Win | GLUE Stock News - StockTitan
Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World
Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat
Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance
Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma
Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance
This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN
Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal
Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada
Novartis adds another degrader, this time from Monte Rosa - BioCentury
This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily
Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat
Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online
Boston Biotech Announces Novartis Collaboration - Streetwise Reports
Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat
Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch
Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN
Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha
Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International
Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart
Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals
Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart
Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India
Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online
Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter
Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive
“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail
Monte Rosa Therapeutics, Inc Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Marketscreener.com
Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs - Reuters
Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Yahoo Finance
Monte Rosa Therapeutics Shares Soar on Novartis Team-Up - Marketscreener.com
Monte Rosa jumps on $150M license deal with Novartis (NASDAQ:GLUE) - Seeking Alpha
Monte Rosa inks $150 million Novartis deal for MRT-6160 By Investing.com - Investing.com Canada
GLUEMonte Rosa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
3.66%
1.11%
자본화:
|
볼륨(24시간):